Northwest Biotherapeutics | NWBO - Beneficio Operativo





Beneficio Operativo Cambio Fecha
Agenus USD 14.4M 19.26M 2025-12
AstraZeneca USD 7.11B 4.14B 2026-03
Bristol-Myers Squibb USD 4.2B 562M 2025-12
Celldex Therapeutics USD -84.44M 2.72M 2026-03
Eisai JPY -10.31B 30.35B 2026-03
Merck USD -1.88B 8.12B 2026-03
Northwest Biotherapeutics USD -14.32M 481K 2025-09
Pfizer USD 4.99B 340M 2026-03
Plus Therapeutics USD -5.74M 1.26M 2025-12
Roche Holding CHF 9.56B 3.8B 2025-12